Beatriz Lopes

Ms. Beatriz Lopes

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RSRafael Silva-Teixeira
Rafael Silva-Teixeira
Mafalda LaranjoMafalda Laranjo
Mafalda Laranjo
BLBeatriz Lopes
Beatriz Lopes
CACatarina Almeida-Ferreira
Catarina Almeida-Ferreira
AGAna Cristina Gonçalves
Ana Cristina Gonçalves
Maria Filomena BotelhoMaria Filomena Botelho
Maria Filomena Botelho

5 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BLBeatriz Lopes
Beatriz Lopes
LOLiam O'Neill
Liam O'Neill
PBPaula Bourke
Paula Bourke
Daniela BoehmDaniela Boehm
Daniela Boehm
The increase in cancer diagnoses and cancer deaths, severe side effects of existing treatments and resistance to traditional treatments have generated a need for new anticancer treatments. Glioblastoma multiforme (GBM) is the most common, malignant and aggressive brain cancer. Despite many innovations regarding GBM treatment, the final outcome is still very poor, making it necessary to develop new therapeutic approaches. Cold atmospheric plasma (CAP) as well as plasma-activated liquids (PAL) are being studied as new possible approaches against cancer. The anticancer activity of PAL such as “plasma-activated water” (PAW) is dependent on the reactive chemical compounds present in the solution. Possible combinatory effects with conventional therapies, such as chemotherapeutics, may expand the potential of PAL for cancer treatment. We aim to explore the therapeutic properties of a combination of PAW and topotecan (TPT), an antineoplastic agent with major cytotoxic effects during the S phase of the cell cycle, on a GBM cancer cell line (U-251mg). Combined treatments with PAW and TPT showed a reduction in the metabolic activity and cell mass, an increase in apoptotic cell death and a reduction in the long-term survival. Single applications of PAW+TPT treatments showed a cytotoxic effect in the short term and an antiproliferative effect in the long term, warranting future exploration of combining PAW with chemotherapeutic agents as new therapeutic approaches.

1 January 2024 in Plasma Medicine
Verified
Journal Article
Open access
PDF file
BLBeatriz Lopes
Beatriz Lopes
FOFiona O'NEill
Fiona O'NEill
LOLiam O'NEill
Liam O'NEill
PBPaula Bourke
Paula Bourke
Daniela BoehmDaniela Boehm
Daniela Boehm
Cold plasma therapy is emerging as an innovative modality, with the potential to exhibit synergistic effects when combined with chemotherapeutic agents. A new plasma-assisted local delivery of oncology drugs was developed to mediate the drug delivery and possibly enhance the drug uptake and chemotherapeutical action. Topotecan (TPT) was selected as the candidate drug because despite the potent antitumor activity, the systemic administration is limited. The influence of the plasma deposition process on the characteristics of TPT, was investigated to determine potential structure and activity changes. Fluorescence analysis showed that the emission spectrum of TPT is altered by modifications to the A-ring, influenced by solvent polarity, pH, and moisture content, while deposition parameters and surface characteristics also played important roles, but no structural changes to the A-ring were indicated with plasma exposure. A TPT solution was sprayed into a non-thermal plasma and deposited onto polystyrene microplates. Results showed that the TPT elution from the microplates into cell culture medium was almost complete and instantaneous. Initial findings with U251-mg glioblastoma cell line model suggest that plasma deposition enhances drug stability without compromising biological activity compared to a wet deposition of TPT. This result was confirmed using High Performance Liquid Chromatography. These results reveal a new mode of delivery for effective topotecan therapeutic use and can open the doors to new combinations for local drug application.